Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: Single- and multiple-dose phase I studies with healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4729-4737

  Brennan, Barbara J ^a   Davies, Brian ^a   Cirrincione Dall, Georgina ^a   Morcos, Peter N ^a   Beryozkina, Anna ^a   Chappey, Colombe ^a   Baldó, Pau Aceves ^b   Lennon Chrimes, Sian ^b   Rayner, Craig R ^c  

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c Roche Products Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; SODIUM CHLORIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSELTAMIVIR; PLACEBOS;

EID: 84865407931     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00200-12     Document Type: Article

References (24)

1. Ariano RE, et al. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182:357-363.
2. Bantia S, et al. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167. (Pubitemid 32230997)
3. Davies BE. 2010. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J. Antimicrob. Chemother. 65(Suppl. 2):ii5-ii10.
4. Farias JA, et al. 2010. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med. 36:1015-1022.
5. F. Hoffmann-La Roche, Ltd. 2011. Tamiflu prescribing information (PI). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm ?fuseaction=Search.Search-Drug-Name. Accessed 25 August 2011.
6. F. Hoffmann-La Roche, Ltd. 2011. Tamiflu summary of product characteristics (SmPC). http://www.medicines.org.uk/emc/. Accessed 25 August 2011.
7. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. 2001. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45:2723-2732. (Pubitemid 32906663)
8. He G, Massarella J, Ward P. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37:471-484. (Pubitemid 30032251)
9. Heinonen S, et al. 2010. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin. Infect. Dis. 51:887-894.
10. Kaiser L, et al. 2003. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med. 163:1667-1672. (Pubitemid 36898954)
11. Kumar D, et al. 2010. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect. Dis. 10:521-526.
12. Lee N, et al. 2010. Outcomes of adults hospitalised with severe influenza. Thorax 65:510-515.
13. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/ 1074/99 (H9N2) influenza viruses. Antiviral Res. 48:101-115.
14. McGeer A, et al. 2007. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin. Infect. Dis. 45:1568-1575. (Pubitemid 351411840)
15. Nicholson KG, et al. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355:1845-1850. (Pubitemid 30311875)
16. Parrott N, et al. 2011. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in the very young. Clin. Pharmacokinet. 50:613-623.
17. Power BM, Forbes AM, van Heerden PV, Ilett KF. 1998. Pharmacokinetics of drugs used in critically ill adults. Clin. Pharmacokinet. 34:25-56. (Pubitemid 28041091)
18. Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN. 2008. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J. Clin. Pharm. 48:935-947. (Pubitemid 352009487)
19. Roberts NA, Wiltshire HR, Mendel DB, Webster RG. 2003. Oseltamivir carboxylate is effective against all subtypes of influenza neuraminidase, poster 135. Poster 3rd Annu. ASM Biodefense Res. Meet. American Society for Microbiology, Washington, DC.
20. Siston AM, et al. 2010. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 303:1517-1525.
21. Treanor JJ, et al. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283:1016-1024. (Pubitemid 30112215)
22. Whitley RJ, et al. 2001. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20:127-133. (Pubitemid 32151932)
23. World Health Organization. 2009. Influenza (seasonal). Fact sheet no. 211. April 2009. World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs211/en. Accessed 25 August 2011.
24. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza et al. 2009. Clinical aspects of pandemic influenza A (H1N1) virus infection. 2010. N. Engl. J. Med. 362:1708-1719.